Furthermore, the association between the foetal genetic deficiency of LCHAD and pregnancy-specific disorders, such as acute fatty liver and preeclampsia, has been reported [49], and this may also therefore represent one additional mechanism in reducing the burden of non-alcoholic fatty liver disease after RYGB. The gene discussed is HADHA; the disease is metabolic dysfunction-associated steatotic liver disease.